Congresos

Título Añoorden descendente
Discovery of new therapies for Buruli ulcer treatment 2017
Repurposing clinically approved cephalosporins for tuberculosis therapy 2017
The D2AMR group: Discovery and development of Antimicrobials and Mechanisms of drug Resistance 2017
Innovative drug discovery and development strategies for antibacterial therapy: a focus on neglected diseases  2017
Preliminary studies to elucidate the mode of action of a new chemical series with antimicrobial activity 2018
Discovery and Development of Antimicrobials and Mechanisms of Drug Resistance 2018
ANTHELMINTIC AVERMECTINS FOR THE TREATMENT OF NON-TUBERCULOUS MYCOBACTERIA INFECTIONS IN CYSTIC FIBROSIS 2018
Anthelmintic avermectins for the treatment of non-tuberculous mycobacteria infections in cystic fibrosis 2018
Caracterización biológica de una nueva serie de compuestos químicos con actividad antimicrobiana 2018
Sesión II: Antimicrobianos (Moderador) 2018
Estudios iniciales para la caracterización del modo de acción molecular de las avermectinas como agentes anti-tuberculosos 2018
Towards the elucidation of rifampicin/betalactam synergistic interactions against M. tuberculosis 2018
Discovery and Development of Antimicrobials and Mechanisms of Drug Resistance 2018
Development of a high-throughput method for synergistic drug combinations screening 2018
Repurposing beta-lactams for buruli ulcer treatment 2018
REPURPOSING BETA-LACTAMS FOR BURULI ULCER TREATMENT 2018
Beta-lactams for Tuberculosis Treatment 2019
Mode of action elucidation studies of a new chemical series active against Mycobacteria and other microbial pathogens 2019
TOWARDS THE ELUCIDATION OF THE MODE OF ACTION OF A NEW CHEMICAL SERIES WITH ANTIMICROBIAL ACTIVITY 2019
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening 2019

Páginas